FD-IN-1 manufacturers
- FD-IN-1
-
- $332.00 / 5mg
-
2025-08-21
- CAS:1646682-14-5
- Min. Order:
- Purity:
- Supply Ability: 10g
|
| | FD-IN-1 Basic information |
| Product Name: | FD-IN-1 | | Synonyms: | FD-IN-1;Benzeneacetic acid, 2-[[3'-[(1S)-1-amino-2-hydroxyethyl][1,1'-biphenyl]-3-yl]methoxy]-;(S)-2-(2-((3'-(1-amino-2-hydroxyethyl)-[1,1'-biphenyl]-3-yl)methoxy)phenyl)acetic acid;FDIN1,FD IN 1 | | CAS: | 1646682-14-5 | | MF: | C23H23NO4 | | MW: | 377.43 | | EINECS: | | | Product Categories: | | | Mol File: | 1646682-14-5.mol |  |
| | FD-IN-1 Chemical Properties |
| Boiling point | 629.4±55.0 °C(Predicted) | | density | 1.251±0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | Soluble in DMSO | | form | Solid | | pka | 4.14±0.10(Predicted) | | color | White to off-white |
| | FD-IN-1 Usage And Synthesis |
| Uses | FD-IN-1 (Compound 12) is an orally bioavailable and selective factor D (FD) inhibitor with an IC50 of 12 nM. Complement FD, a highly specific S1 serine protease, plays a central role in the alternative complement pathway of the innate immune system. FD-IN-1 also inhibits factor XIa (FXIa) and Tryptase β2 with IC50s of 7.7 and 6.5 μM, respectively[1]. | | Biological Activity | FD-IN-1 (Compound 12) is a potent, orally active complement factor D (FD) inhibitor with IC50 of 12 nM.It also inhibits factor XIa (FXIa) and tryptase β2 with IC50 of 7.7 and 6.5 μM, respectively. | | in vitro | FD-IN-1 (Compound 12) exhibits functional inhibition of AP activation (IC 50 =0.26 μM) in vitro in a membrane attack complex (MAC) deposition assay using 50% human whole blood (WB). | | in vivo | FD-IN-1 (Compound 12) demonstrates systemic suppression of AP activation in a lipopolysaccharide-induced alternative complement pathway (AP) activation model as well as local ocular suppression in intravitreal injection-induced AP activation model in mice expressing human FD.
FD-IN-1 (Compound 12) exhibits high oral bioavailability (C57BL6 mice 83%, Beagle dogs 70%) following oral administration (mice and dogs 10 mg/kg).
FD -IN-1 (Compound 12) exhibits terminal elimination half-lives (C57BL6 mice 1.6 h and Beagle dogs 3.8 h) following intravenous administration (mice and dogs 1 mg/kg). b> | Animal Model: | Human FD knock-in mice | | Dosage: | 3 and 10 mg/kg | | Administration: | Oral gavage | | Result: | The AP pathway was fully inhibited for up to 10 h at the 10 mg/kg dose. | table> | References | [1] Karki RG, et al. Design, Synthesis, and Preclinical Characterization of Selective Factor D Inhibitors Targeting the Alternative Complement Pathway. J Med Chem. 2019 May 9;62(9):4656-4668. DOI:10.1021/acs.jmedchem.9b00271 |
| | FD-IN-1 Preparation Products And Raw materials |
|
|
Tag:FD-IN-1(1646682-14-5)
Related Product Information
|
|
|
According to the laws, regulations and policies related to "patent products", the sale of this product is prohibited!
ChemicalBook prompt
The patent owner or licensee of the product has not released any relevant information for the time being.
|